查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2004646

粘合劑輔料市場：按類型、劑型、等級和應用分類－2026-2032年全球市場預測

Binders Excipients Market by Type, Form, Grade, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，粘合劑輔料市場價值將達到 21.8 億美元，到 2026 年將成長到 23.7 億美元，到 2032 年將達到 42.4 億美元，複合年成長率為 9.94%。

主要市場統計數據
基準年 2025 21.8億美元
預計年份：2026年 23.7億美元
預測年份 2032 42.4億美元
複合年成長率 (%) 9.94%

對粘合劑輔料採取策略性方法，概述其在產品性能、可製造性和供應鏈韌性方面的多方面作用。

粘合劑輔料有助於維持口服固體製劑和日益多樣化的膳食補充劑的機械完整性、可生產性和患者療效。這些材料的作用遠不止於簡單的黏合，它們還能在各種加工條件下調節粉末的流動性、可壓縮性、崩壞行為和穩定性。隨著配方日益複雜，製程也日益精細化和標準化，了解粘合劑的功能對於配方研發人員和採購負責人都至關重要。

技術創新、監管透明度和供應鏈韌性如何共同重塑粘合劑輔料的選擇和供應商策略。

粘合劑輔料領域正經歷變革，這主要受技術、監管和供應鏈趨勢的驅動。聚合物化學和功能性澱粉改質技術的進步，使得粘合劑能夠提供更最佳化的釋放曲線、更高的可壓縮性和更低的潤滑劑敏感性。同時，連續直接壓片和高通量壓片等生產技術的創新，也對黏合劑提出了更高的要求，即需要具有可預測的流變特性和穩定的製程窗口的粘合劑。

本研究評估了關稅調整和貿易政策轉變如何重塑整個粘合劑供應鏈的採購行為、供應商多元化和庫存策略。

關稅措施和貿易政策調整的推出將對粘合劑輔料的生態系統產生深遠影響，可能波及原料成本、供應商籌資策略和庫存計畫。關稅往往會增加進口添加劑的成本，迫使製造商重新評估其供應商網路並考慮在地採購替代方案。關稅的不可預測性上漲可能需要更頻繁地審查合約條款、前置作業時間和總到岸成本。

為了支持配方設計和採購決策，我們提供了對綜合細分的見解，將黏合劑的化學性質、調查方法、物理形態和品質等級結合起來。

精確了解黏合劑的分類對於協調配方目標、生產平台和法規遵循至關重要。在考慮基於類型的選擇時，配方開發人員會根據其獨特的功能特性評估各種材料，例如藻酸鹽、纖維素衍生物、樹膠和凝膠、聚乙烯吡咯烷酮、澱粉、醣類和多元醇。藻酸鹽具有獨特的水合和凝膠化行為，有利於緩釋製劑的開發；纖維素衍生物因其穩定的可壓縮性和成膜性能而備受青睞。樹膠和凝膠在濕式製粒條件下可以賦予製劑黏度和黏合性能；聚乙烯吡咯烷酮具有強大的乾法和溶液黏合性能，適用於多種生產方法。澱粉仍然是一種用途廣泛的基礎粘合劑，在成本和生物分解性方面具有明顯的優勢；而醣類和多元醇在某些劑型中通常兼具粘合劑和風味調節輔料的雙重作用。

影響美洲、歐洲、中東和非洲以及亞太市場粘合劑採購、監管合規和製造夥伴關係的區域趨勢。

區域趨勢對粘合劑採購、監管要求和生產策略有顯著影響。在美洲，成熟的製藥產業叢集將先進的生產能力與完善的法規結構相結合，從而促進了供應商和契約製造之間的密切合作。北美市場更傾向於那些能夠展現供應鏈透明度、嚴格的品管體係以及長期生產能力和技術支援的供應商。另一方面，拉丁美洲國家則呈現不同的趨勢，本地化生產不斷成長，對價格可負擔性和供應穩定性的重視程度日益提高，迫使跨國公司相應地調整其採購和分銷策略。

具競爭力的供應商策略，結合聯合技術開發、嚴格的品質系統和永續性舉措，以確保配方開發和採購夥伴關係。

如今，黏合劑供應商之間的競爭焦點在於技術服務、品質保證和供應可靠性的綜合體現。領先的製造商透過投資分析能力（例如顆粒表徵、流變學分析和穩定性測試）來脫穎而出，從而能夠支援複雜的配方開發和等效性驗證。提供應用實驗室和聯合開發服務的供應商可以幫助客戶縮短開發週期，並在新材料合格或更換供應商時降低風險。

領導者採取切實可行的策略步驟，協調技術能力、供應商多元化和管治體系，以確保黏合劑的穩定供應和產品品質。

產業領導企業應優先考慮整合技術開發、供應商多元化和法規遵循的整合策略。首先，應建立跨職能的黏合劑管治架構，將配方開發、品質保證、採購和法規遵循納入單一決策流程。這種方法可以降低引入替代供應商時出現意外問題的風險，並透過並行測試和文件共用縮短合格週期。

採用混合方法研究途徑，結合相關人員訪談、技術文獻整合和供應商能力評估，以獲得可靠的見解。

本研究採用結構化的調查方法進行綜合分析，該方法結合了對關鍵相關人員的訪談、技術文獻回顧和供應商能力評估，從而得出嚴謹且可操作的分析結果。關鍵輸入包括與配方科學家、採購經理和法規專家的討論，他們的實踐經驗被用於解讀材料功能、合格障礙和籌資策略。這些定性輸入與技術文獻、生產案例研究以及公開的黏合劑化學法規指南進行交叉比對，以確保研究結果具有紮實的技術基礎。

總結指出，黏合劑輔料定位為跨職能優先事項，將粘合劑性能、籌資策略和供應鏈彈性連結起來。

粘合劑輔料是一類重要的策略性材料，其選擇會影響配方性能、製程效率、法規遵循性和供應鏈韌性。粘合劑的化學性質和形態差異會導致功能上的差異，這對直接壓片、濕式製粒和乾式製粒等生產製程平台有著顯著的影響。同時，膳食補充劑和藥品對黏合劑等級的差異也會影響相關的文件要求和供應商合格認證。將技術評估與籌資策略和法規遵循計劃相結合的企業可以降低風險並縮短產品上市時間。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：粘合劑市場：按類型分類

  • 海藻酸鹽
  • 纖維素衍生物
  • 口香糖和凝膠
  • 聚乙烯吡咯烷酮
  • 澱粉
  • 醣類和多元醇

第9章：粘合劑市場：依劑型分類

  • 乾燥粘合劑
  • 液體粘合劑

第10章：粘合劑市場：依等級分類

  • 營養保健品
  • 製藥

第11章：粘合劑市場：依應用領域分類

  • 直接壓縮
  • 乾式製粒
  • 口服固體製劑
    • 膠囊
    • 藥片
  • 濕式製粒

第12章：粘合劑市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：粘合劑輔料市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：粘合劑市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 美國：粘合劑輔料市場

第16章 中國：粘合劑輔料市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Archer Daniels Midland Company
  • Asahi Kasei Corporation
  • Ashland Global Holdings Inc.
  • Avantor, Inc.
  • BASF SE
  • Cargill, Incorporated
  • Colorcon, Inc.
  • Daicel Corporation
  • DFE Pharma GmbH & Co. KG
  • Dow Chemical Company
  • DuPont de Nemours, Inc.
  • Evonik Industries AG
  • Fuji Chemical Industries Co., Ltd.
  • Ingredion Incorporated
  • JRS PHARMA GmbH & Co. KG
  • Kerry Group plc
  • Lubrizol Corporation
  • Matsutani Chemical Industry Co., Ltd.
  • Meggle Group GmbH
  • Merck KGaA
  • Nippon Soda Co., Ltd.
  • Roquette Freres SA
  • Shin-Etsu Chemical Co., Ltd.
  • Sigachi Industries Limited
  • SPI Pharma, Inc.
Product Code: MRR-742BD517BD05

The Binders Excipients Market was valued at USD 2.18 billion in 2025 and is projected to grow to USD 2.37 billion in 2026, with a CAGR of 9.94%, reaching USD 4.24 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.18 billion
Estimated Year [2026] USD 2.37 billion
Forecast Year [2032] USD 4.24 billion
CAGR (%) 9.94%

A strategic orientation to binder excipients that outlines their multifaceted roles in product performance, manufacturability, and supply chain resilience

Binder excipients underpin the mechanical integrity, manufacturability, and patient performance of oral solid dosage forms and a growing range of nutraceutical products. These materials function beyond simple adhesion; they mediate powder flow, compressibility, disintegration behavior, and stability under varied processing conditions. With formulation complexity increasing and process intensification becoming standard, understanding binder functionality is essential for both formulation scientists and sourcing professionals.

Across pharmaceutical and nutraceutical contexts, binders influence formulation selection from early development through commercialization. The choice between polymeric binders and traditional starch-based systems drives downstream process settings, tableting speeds, and even coating behavior. Consequently, binder selection has ripple effects across quality by design frameworks, regulatory strategy, and cost management. Practitioners must therefore evaluate binders not only by composition and grade but by how they interact with active ingredients, excipients, and processing technologies.

Recent shifts in material science and regulatory expectations have intensified scrutiny on excipient characterization, traceability, and supplier governance. Simultaneously, manufacturing paradigms such as continuous processing and direct compression place new functional demands on binder performance. This introduction frames binder excipients as a strategic category whose selection and supply chain management materially affect product performance, time to market, and operational resilience.

How technological innovation, regulatory transparency, and supply chain resilience are jointly reshaping binder excipient selection and supplier strategies

The landscape for binder excipients is experiencing transformative shifts driven by technological, regulatory, and supply chain dynamics. Advances in polymer chemistry and functional starch modification are enabling binders that deliver tailored release profiles, improved compressibility, and reduced lubricant sensitivity. At the same time, manufacturing innovation-such as continuous direct compression and high-throughput tableting-demands binders with predictable rheology and robust process windows.

Regulatory expectations are shifting toward greater transparency and traceability for excipient sourcing, prompting suppliers to invest in enhanced documentation, controlled material attributes, and third-party testing. This trend is paralleled by increasing scrutiny of impurity profiles and leachables, which in turn has accelerated the adoption of more rigorously characterized grades for pharmaceutical applications. As a result, the boundary between pharmaceutical-grade and nutraceutical-grade excipients is becoming more defined in practice, even if regulatory regimes differ by jurisdiction.

Supply chain resilience has emerged as a decisive factor. Disruptions have highlighted the need for diversified sourcing strategies and supplier risk assessment frameworks that extend beyond price and lead time. Companies are re-evaluating contracts, qualifying secondary sources, and seeking longer-term strategic partnerships with suppliers that can demonstrate capacity, quality systems, and logistical reliability. These combined forces are reshaping how formulators and procurement teams evaluate binder choices, prioritizing functional performance alongside regulatory readiness and supply continuity.

Assessing how tariff adjustments and trade policy shifts reshape sourcing behaviors, supplier diversification, and inventory strategies across binder supply chains

The introduction of tariff measures and trade policy adjustments can have wide-ranging effects on the binder excipient ecosystem, affecting raw material costs, supplier sourcing strategies, and inventory planning. Tariffs tend to raise the cost base for imported excipients, which in turn pressures manufacturers to reassess supplier networks and examine local sourcing alternatives. When customs duties increase unpredictably, contract terms, lead times, and total landed cost calculations require more frequent revision.

Manufacturers often respond to tariff-driven cost pressures by diversifying supplier footprints to include domestic producers or free trade zone partners that mitigate duty exposure. This reconfiguration can improve resilience but may also introduce variability in excipient attributes if alternate suppliers use different production technologies or raw materials. As a result, formulation teams must invest in bridging development activities and equivalence testing to ensure that substitutions do not compromise tablet integrity, dissolution performance, or stability.

Tariffs also influence inventory strategies. Companies may opt for strategic stockpiling of critical binder grades to buffer against short-term cost volatility, but this creates additional working capital and storage considerations as well as shelf-life management obligations. In parallel, procurement functions are renegotiating long-term agreements and exploring hedging mechanisms with suppliers to smooth the impact of tariff unpredictability. These cumulative adjustments highlight the need for integrated commercial and technical decision-making to preserve both product quality and margin under shifting trade conditions.

Integrated segmentation insights that align binder chemistries, application methodologies, physical forms, and quality grades to support formulation and sourcing decisions

A nuanced understanding of binder segmentation is essential for aligning formulation goals, manufacturing platforms, and regulatory compliance. When considering type-based selection, formulators evaluate materials such as alginates, cellulose derivatives, gums and gels, polyvinylpyrrolidone, starch, and sugars and polyols for their distinct functional attributes. Alginates offer unique hydration and gelation behaviors beneficial for controlled-release applications, while cellulose derivatives are valued for consistent compressibility and film-forming capacity. Gums and gels can impart viscosity and binding under moist granulation regimes, and polyvinylpyrrolidone provides strong dry binding and solution-binding properties that suit diverse manufacturing methods. Starch remains a versatile baseline binder with clear advantages in cost and biodegradability, whereas sugars and polyols often serve dual roles as binders and taste-modifying excipients in certain dose forms.

Application-driven segmentation influences both selection and performance expectations. Direct compression demands binders that support flow, compressibility, and tablet strength without additional granulation steps, whereas dry granulation requires materials that withstand compaction forces and minimize friability. Wet granulation introduces a separate set of criteria where the binder's solubility, drying profile, and interaction with active ingredients affect granule quality and downstream processing. Oral solid dosage forms span capsule and tablet presentations, each with unique disintegration and stability requirements; capsule formulations place greater emphasis on binder interaction with fill material and capsule shell integrity, while tablet formats focus on compaction dynamics and coating compatibility.

Form selection-dry binder versus liquid binder-further shapes development pathways and equipment choices. Dry binders integrate readily into powder blends and simplify handling for continuous processing, but they may require careful control of particle size and moisture content. Liquid binders are often used in wet granulation to achieve rapid granule formation and uniform distribution, though they introduce solvent handling and drying considerations that can affect process throughput and cost. Finally, grade differentiation between nutraceutical and pharmaceutical influences documentation, quality systems, and supplier qualification burdens. Pharmaceutical-grade binders necessitate tighter control over impurities, robust traceability, and adherence to pharmacopoeial standards, while nutraceutical-grade materials may permit more flexibility but still require consistent functional performance for consumer-facing products.

Transitioning across these segmentation axes requires cross-functional collaboration. Formulation scientists must work alongside procurement, quality, and regulatory teams to ensure that binder selection meets technical objectives while aligning with supplier capabilities and compliance commitments. Equivalence studies, small-scale process characterization, and documented supplier audits are practical tools to manage the intersection of type, application, form, and grade in a cohesive development and manufacturing plan.

Regional dynamics that shape binder sourcing, regulatory conformity, and manufacturing partnerships across the Americas, Europe Middle East Africa, and Asia-Pacific markets

Regional dynamics exert a strong influence on binder sourcing, regulatory expectations, and manufacturing strategy. In the Americas, established pharmaceutical clusters combine advanced manufacturing capabilities with mature regulatory frameworks, enabling close collaboration between suppliers and contract manufacturers. North American markets emphasize supply chain transparency, rigorous quality management systems, and a preference for suppliers that can demonstrate long-term capacity and technical support. Latin American countries present different dynamics, with increasing local manufacturing and a growing emphasis on affordability and supply security, prompting multinational companies to adapt procurement and distribution strategies accordingly.

Across Europe, the Middle East & Africa, regulatory harmonization and stringent pharmacopoeial standards set high bars for excipient documentation and traceability. European markets often lead in the adoption of sustainability criteria and stricter impurity controls, influencing supplier investments in greener manufacturing practices and enhanced analytical characterization. In parts of the Middle East and Africa, reliance on imports for specialized binder grades continues, but regional hubs and free trade zones are emerging that can reduce lead times and tariff exposure for nearby markets. These regional nuances require suppliers and manufacturers to calibrate their technical dossiers and logistical arrangements to meet distinctive regulatory and commercial expectations.

Asia-Pacific combines diverse market maturity levels with large-scale manufacturing capacity and innovation in raw material processing. Major producers of traditional and novel binder chemistries are located in this region, supplying global supply chains with cost-competitive options while also accelerating local innovation in biopolymers and modified starch technologies. Regional regulatory frameworks vary considerably, and companies operating across Asia-Pacific must navigate differing registration requirements, standards, and import controls. Together, these regional characteristics shape how companies prioritize supplier qualification, technical support, and local manufacturing partnerships to achieve both cost efficiency and regulatory compliance.

Competitive supplier strategies that combine technical co-development, stringent quality systems, and sustainability credentials to win formulation and procurement partnerships

Competitive dynamics among binder suppliers now centers on a combination of technical service, quality assurance, and supply reliability. Leading manufacturers differentiate through investments in analytical capabilities, such as particle characterization, rheological profiling, and stability testing, which enable them to support complex formulation development and equivalence demonstrations. Suppliers that offer application laboratories and co-development services help customers shorten development cycles and reduce risk when qualifying new materials or switching sources.

Quality systems and regulatory documentation are critical competitive levers. Firms that maintain comprehensive certificates of analysis, robust change control processes, and demonstrable supplier audits tend to win longer-term contracts with pharmaceutical customers who require traceability and compliance. In parallel, companies that can provide multiple grades-spanning nutraceutical to pharmaceutical-with clear quality delineation are well-positioned to serve diverse client segments. Strategic partnerships and long-term supply agreements are increasingly common, reflecting customer demand for predictable lead times and contingency planning.

Sustainability and corporate responsibility are emerging differentiators. Suppliers that adopt greener manufacturing processes, reduce solvent use, and demonstrate responsible sourcing of botanical and starch feedstocks appeal to customers who incorporate environmental criteria into procurement decisions. As procurement organizations elevate supplier risk management and environmental considerations, firms that can align technical performance with sustainability credentials secure competitive advantage. Moreover, the ability to scale production to support both small-batch innovation work and high-volume commercial supply remains a critical capability for suppliers seeking to serve global customers.

Actionable strategic steps for leaders to align technical capability, supplier diversification, and governance frameworks to secure binder availability and product quality

Industry leaders should prioritize an integrated strategy that aligns technical development, supplier diversification, and regulatory readiness. Begin by implementing a cross-functional binder governance framework that brings formulation scientists, quality assurance, procurement, and regulatory affairs into a single decision-making loop. This approach reduces the risk of downstream surprises when substitute suppliers are introduced and accelerates qualification timelines through concurrent testing and documentation sharing.

Investments in analytical and application support capabilities pay dividends. Establishing in-house or collaborative labs for rheology, particle size distribution, and compaction analysis enables rapid equivalence testing and accelerates scale-up. Pair technical investments with scenario-based procurement planning that evaluates supplier capacity, dual-sourcing options, and logistics contingencies to mitigate trade policy volatility and capacity constraints. These combined measures help maintain continuity of supply while preserving formulation performance.

Adopt a supplier engagement model that rewards transparency and continuous improvement. Prefer suppliers who publish robust quality documentation, participate in joint development projects, and commit to sustainability improvements. Where possible, negotiate flexible commercial terms that incorporate quality guarantees, contractual change control, and collaborative planning provisions. Finally, incorporate binder considerations early in product development strategies to exploit formulation synergies, reduce late-stage substitutions, and ensure that supply chain decisions support long-term product performance and compliance objectives.

A mixed-method research approach combining stakeholder interviews, technical literature synthesis, and supplier capability assessments for dependable insights

This research synthesis relies on a structured methodology that integrates primary stakeholder interviews, technical literature review, and supplier capability assessments to produce a rigorous, actionable analysis. Primary inputs included discussions with formulation scientists, procurement leads, and regulatory specialists whose operational insights informed the interpretation of material functionality, qualification hurdles, and sourcing strategies. These qualitative inputs were triangulated with technical literature on binder chemistry, manufacturing case studies, and public regulatory guidance to ensure findings are grounded in robust technical context.

Supplier capability assessments focused on production processes, quality management systems, and the availability of application support services. Where applicable, audits and manufacturer documentation were reviewed to verify traceability practices and conformity with relevant pharmacopoeial standards. The methodology also incorporated scenario analysis to explore the operational impacts of supply disruptions and policy shifts, enabling the development of practical mitigation recommendations.

Throughout the process, an emphasis was placed on reproducible evaluation criteria such as functional performance metrics, regulatory readiness indicators, and supply chain resilience measures. This mixed-method approach ensures that the insights presented are both technically defensible and directly applicable to commercial decision-making and formulation development planning.

Concluding synthesis that positions binder excipients as a cross-functional priority linking formulation performance, procurement strategy, and supply chain resilience

Binder excipients represent a strategic category whose selection affects formulation performance, process efficiency, regulatory compliance, and supply chain resilience. Functional differentiation across binder chemistries and forms creates meaningful implications for manufacturing platforms such as direct compression, wet granulation, and dry granulation, while grade differentiation between nutraceutical and pharmaceutical uses alters documentation and supplier qualification demands. Companies that align technical evaluation with procurement strategy and regulatory planning can reduce risk and accelerate time to market.

The evolving landscape calls for closer collaboration between formulation and procurement teams, deeper investment in analytical capabilities, and proactive supplier engagement that emphasizes transparency and capacity assurance. Regional dynamics and trade policy shifts further underline the necessity of diversified sourcing strategies and scenario-based inventory planning. Taken together, these conclusions point to a single practical imperative: treat binder excipients as a cross-functional priority rather than a purely commodity purchase, and embed their evaluation early in product development workflows to secure performance and supply continuity.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Binders Excipients Market, by Type

  • 8.1. Alginates
  • 8.2. Cellulose Derivatives
  • 8.3. Gums And Gels
  • 8.4. Polyvinylpyrrolidone
  • 8.5. Starch
  • 8.6. Sugars And Polyols

9. Binders Excipients Market, by Form

  • 9.1. Dry Binder
  • 9.2. Liquid Binder

10. Binders Excipients Market, by Grade

  • 10.1. Nutraceutical
  • 10.2. Pharmaceutical

11. Binders Excipients Market, by Application

  • 11.1. Direct Compression
  • 11.2. Dry Granulation
  • 11.3. Oral Solid Dosage
    • 11.3.1. Capsule
    • 11.3.2. Tablet
  • 11.4. Wet Granulation

12. Binders Excipients Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Binders Excipients Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Binders Excipients Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Binders Excipients Market

16. China Binders Excipients Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Archer Daniels Midland Company
  • 17.6. Asahi Kasei Corporation
  • 17.7. Ashland Global Holdings Inc.
  • 17.8. Avantor, Inc.
  • 17.9. BASF SE
  • 17.10. Cargill, Incorporated
  • 17.11. Colorcon, Inc.
  • 17.12. Daicel Corporation
  • 17.13. DFE Pharma GmbH & Co. KG
  • 17.14. Dow Chemical Company
  • 17.15. DuPont de Nemours, Inc.
  • 17.16. Evonik Industries AG
  • 17.17. Fuji Chemical Industries Co., Ltd.
  • 17.18. Ingredion Incorporated
  • 17.19. JRS PHARMA GmbH & Co. KG
  • 17.20. Kerry Group plc
  • 17.21. Lubrizol Corporation
  • 17.22. Matsutani Chemical Industry Co., Ltd.
  • 17.23. Meggle Group GmbH
  • 17.24. Merck KGaA
  • 17.25. Nippon Soda Co., Ltd.
  • 17.26. Roquette Freres S.A.
  • 17.27. Shin-Etsu Chemical Co., Ltd.
  • 17.28. Sigachi Industries Limited
  • 17.29. SPI Pharma, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BINDERS EXCIPIENTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BINDERS EXCIPIENTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY GRADE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BINDERS EXCIPIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BINDERS EXCIPIENTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY ALGINATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY ALGINATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY ALGINATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY CELLULOSE DERIVATIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY CELLULOSE DERIVATIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY CELLULOSE DERIVATIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY GUMS AND GELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY GUMS AND GELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY GUMS AND GELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY POLYVINYLPYRROLIDONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY POLYVINYLPYRROLIDONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY POLYVINYLPYRROLIDONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY STARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY STARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY STARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY SUGARS AND POLYOLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY SUGARS AND POLYOLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY SUGARS AND POLYOLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY DRY BINDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY DRY BINDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY DRY BINDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY LIQUID BINDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY LIQUID BINDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY LIQUID BINDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY NUTRACEUTICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY NUTRACEUTICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY NUTRACEUTICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY DIRECT COMPRESSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY DIRECT COMPRESSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY DIRECT COMPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY DRY GRANULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY DRY GRANULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY DRY GRANULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY WET GRANULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY WET GRANULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY WET GRANULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS BINDERS EXCIPIENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS BINDERS EXCIPIENTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS BINDERS EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS BINDERS EXCIPIENTS MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS BINDERS EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS BINDERS EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA BINDERS EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA BINDERS EXCIPIENTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA BINDERS EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA BINDERS EXCIPIENTS MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA BINDERS EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA BINDERS EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA BINDERS EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA BINDERS EXCIPIENTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA BINDERS EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA BINDERS EXCIPIENTS MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA BINDERS EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA BINDERS EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA BINDERS EXCIPIENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA BINDERS EXCIPIENTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA BINDERS EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA BINDERS EXCIPIENTS MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA BINDERS EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA BINDERS EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE BINDERS EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE BINDERS EXCIPIENTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE BINDERS EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE BINDERS EXCIPIENTS MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE BINDERS EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE BINDERS EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST BINDERS EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST BINDERS EXCIPIENTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST BINDERS EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST BINDERS EXCIPIENTS MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST BINDERS EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST BINDERS EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA BINDERS EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA BINDERS EXCIPIENTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA BINDERS EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA BINDERS EXCIPIENTS MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA BINDERS EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA BINDERS EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC BINDERS EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC BINDERS EXCIPIENTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC BINDERS EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC BINDERS EXCIPIENTS MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC BINDERS EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC BINDERS EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN BINDERS EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN BINDERS EXCIPIENTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN BINDERS EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN BINDERS EXCIPIENTS MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN BINDERS EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN BINDERS EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 111. GCC BINDERS EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GCC BINDERS EXCIPIENTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. GCC BINDERS EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 114. GCC BINDERS EXCIPIENTS MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 115. GCC BINDERS EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. GCC BINDERS EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION BINDERS EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION BINDERS EXCIPIENTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION BINDERS EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION BINDERS EXCIPIENTS MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION BINDERS EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION BINDERS EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS BINDERS EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS BINDERS EXCIPIENTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS BINDERS EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS BINDERS EXCIPIENTS MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS BINDERS EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS BINDERS EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 129. G7 BINDERS EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. G7 BINDERS EXCIPIENTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. G7 BINDERS EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 132. G7 BINDERS EXCIPIENTS MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 133. G7 BINDERS EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. G7 BINDERS EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 135. NATO BINDERS EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. NATO BINDERS EXCIPIENTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. NATO BINDERS EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 138. NATO BINDERS EXCIPIENTS MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 139. NATO BINDERS EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. NATO BINDERS EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL BINDERS EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES BINDERS EXCIPIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES BINDERS EXCIPIENTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES BINDERS EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES BINDERS EXCIPIENTS MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES BINDERS EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES BINDERS EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA BINDERS EXCIPIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA BINDERS EXCIPIENTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA BINDERS EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA BINDERS EXCIPIENTS MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA BINDERS EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA BINDERS EXCIPIENTS MARKET SIZE, BY ORAL SOLID DOSAGE, 2018-2032 (USD MILLION)